<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196179</url>
  </required_header>
  <id_info>
    <org_study_id>ANG-3070-001</org_study_id>
    <nct_id>NCT04196179</nct_id>
  </id_info>
  <brief_title>ANG-3070 in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of ANG-3070 in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angion Biomedica Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angion Biomedica Corp</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study, to assess the safety, tolerability, pharmacokinetics, and food&#xD;
      effect of single and multiple ascending doses of ANG-3070 in healthy adult participants.&#xD;
&#xD;
      This study is comprised of 12 cohorts. 5 single ascending dose (SAD) cohorts 6multiple&#xD;
      ascending dose (MAD) cohorts, and 1 single dose food effect (FE) cross-over cohort Each&#xD;
      cohort will have a total of 8 subjects: SAD and MAD (2 subjects receiving placebo and 6&#xD;
      subjects receiving active ANG-3070)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 study, to assess the safety, tolerability, pharmacokinetics, and food&#xD;
      effect of single and multiple ascending doses of ANG-3070 in healthy adult participants.&#xD;
&#xD;
      Each cohort will have a total of 8 subjects: SAD and MAD (2 subjects receiving placebo and 6&#xD;
      subjects receiving active ANG-3070). The study design employs sentinel dosing with 2 subjects&#xD;
      (1 placebo, 1 active treatment) at least 24 hours prior to remainder of cohort for dose&#xD;
      cohort 1.&#xD;
&#xD;
      SAD cohorts are defined as follows, with the FE crossover occurring for participants in&#xD;
      cohort A3 on Day 15 and in cohort D1 on Day 5:&#xD;
&#xD;
      A1 ANG-3070 50 mg (n=6) / Placebo (n=2) A2 ANG-3070 100 mg (n=6) / Placebo (n=2) A3 ANG-3070&#xD;
      200 mg (n=6) / Placebo (n=2) A3 Day 15ANG-3070 200mg (n=6) / Placebo (n=2) A4 ANG-3070 400 mg&#xD;
      (n=6) / Placebo (n=2) A5 Day 1 ANG-3070 600 mg (n=6) / Placebo (n=2) D1 Day 1 ANG-3070 600 mg&#xD;
      Single Dose (n=6) / Placebo (n=2) D1 Day 5 (ANG-3070 600 mg Single Dose (n=6) / Placebo (n=2)&#xD;
&#xD;
      MAD cohorts will receive drug or placebo twice daily for 14 consecutive days (Day 1 to Day&#xD;
      14) or drug or placebo once daily for 14 consecutive days (Day 1 to Day 14) as follows:&#xD;
&#xD;
      B1 ANG-3070 50 mg BID (n=6) / Placebo (n=2) B2 ANG-3070 100 mg BID (n=6) / Placebo (n=2) B3&#xD;
      ANG-3070 250 mg BID (n=6) / Placebo (n=2) B4 ANG-3070 500 mg BID (n=6) / Placebo (n=2) C1&#xD;
      ANG-3070 400 mg QD (n=6) / Placebo (n=2) C2 ANG-3070 600 mg QD (n=6) / Placebo (n=2)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2019</start_date>
  <completion_date type="Actual">March 10, 2021</completion_date>
  <primary_completion_date type="Actual">November 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Adverse Events</measure>
    <time_frame>Up to the Follow Up visit 8 days after the last study drug administration</time_frame>
    <description>Difference versus placebo in the number of subjects with adverse events to evaluate safety and tolerability of ANG3070.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Vital Signs</measure>
    <time_frame>Up to the Follow Up visit 8 days after the last study drug administration</time_frame>
    <description>Difference versus placebo in the number of subjects with abnormal vital signs to evaluate safety and tolerability of ANG3070.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Physical Exam</measure>
    <time_frame>Up to the Follow Up visit 8 days after the last study drug administration</time_frame>
    <description>Difference versus placebo in the number of subjects with abnormal Physical examination to evaluate safety and tolerability of ANG3070</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Lab Values</measure>
    <time_frame>Up to the Follow Up visit 8 days after the last study drug administration</time_frame>
    <description>Difference versus placebo in the number of subjects with abnormal lab values to evaluate safety and tolerability of ANG3070.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in ECG QT interval</measure>
    <time_frame>Up to the Follow Up visit 8 days after the last study drug administration</time_frame>
    <description>Difference versus placebo in the number of subjects with abnormal ECG QT interval to evaluate safety and tolerability of ANG3070</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess PK</measure>
    <time_frame>Up to the Follow Up visit 8 days after the last study drug administration</time_frame>
    <description>To assess the pharmacokinetics (PK) of single and multiple ascending doses of ANG-3070 and to evaluate the effect of a high fat meal on the PK of a single dose of ANG-3070 administered to healthy adult participants</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A1 Day 1 ANG-3070 50 mg (n=6) / Placebo (n=2) Oral&#xD;
A2 Day 1 ANG-3070 100 mg (n=6) / Placebo (n=2) Oral&#xD;
A3 Day 1 ANG-3070 200 mg (n=6) / Placebo (n=2) Oral&#xD;
Day 15 ANG-3070 200mg (n=6) / Placebo (n=2) Oral&#xD;
A4 Day 1 ANG-3070 400 mg (n=6) / Placebo (n=2) Oral&#xD;
A5 Day 1 ANG-3070 600 mg (n=6) / Placebo (n=2) Oral&#xD;
D1 Single Dose Food Effect: Day 1 ANG 3070 600 mg *with and without food* (n=6)/ Placebo (n=2) Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B1 ANG-3070 50 mg BID (n=6) / Placebo (n=2)&#xD;
B2 ANG-3070 100 mg BID (n=6) / Placebo (n=2)&#xD;
B3 ANG-3070 250 mg BID (n=6) / Placebo (n=2)&#xD;
B4 ANG-3070 500 mg, BID (n=6)/ Placebo (n=2)&#xD;
C1 ANG-3070 400 mg, QD(n=6)/ Placebo (n=2)&#xD;
C2 ANG-3070 600 mg, QD (n=6)/ Placebo (n=2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANG3070</intervention_name>
    <description>ANG-3070 drug product is a an immediate release oral solid. The drug product consists of a Size 00 Swedish orange capsule containing drug substance (10 mg, 50 mg, or 250 mg) with no excipients.</description>
    <arm_group_label>MAD</arm_group_label>
    <arm_group_label>SAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>ANG-3070 placebo capsules visually match the drug product.</description>
    <arm_group_label>MAD</arm_group_label>
    <arm_group_label>SAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female volunteers, aged 18 to 65 years (inclusive at the time of&#xD;
             informed consent);&#xD;
&#xD;
          2. Participants must be in good general health, with no significant medical history, have&#xD;
             no clinically significant abnormalities on physical examination at Screening and/or&#xD;
             before administration of the initial dose of study drug; and&#xD;
&#xD;
          3. Participants must have a minimum body weight of 50 kg and a Body Mass Index (BMI)&#xD;
             between ≥18.0 and ≤32.0 kg/m2 at Screening;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating at Screening or planning to become pregnant (self or partner) at&#xD;
             any time during the study, including the follow-up period;&#xD;
&#xD;
          2. Prior or ongoing medical conditions, medical history, physical findings, or laboratory&#xD;
             abnormality that, in the Investigator's (or delegate's) opinion, could adversely&#xD;
             affect the safety of the participant;&#xD;
&#xD;
          3. History of gastrointestinal (GI) disorders such as celiac disease, atrophic gastritis,&#xD;
             lactose intolerance, and Helicobacter (H.) pylori infection;&#xD;
&#xD;
          4. Presence of any underlying physical or psychological medical condition that, in the&#xD;
             opinion of the Investigator, would make it unlikely that the participant will comply&#xD;
             with the protocol or complete the study per protocol;&#xD;
&#xD;
          5. Any surgical or medical condition that could interfere with the absorption,&#xD;
             distribution, metabolism, or excretion of the study drug;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shakil Aslam, MD</last_name>
    <role>Study Director</role>
    <affiliation>Angion Biomedica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nucleus Network, VIC</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

